Abstracts portive care were cost-drivers in total medical costs during chemotherapy. In this study, we comprehensively investigated medical costs from diagnosis through terminal care in patients with advanced or recurrent gastric cancer. METHODS: Patients with advanced or recurrent gastric cancer who received the newly developed oral fluoropyrimidine TS-1 or conventional intravenous chemotherapy were identified on the basis of ordering system data at Showa University Hospital from January 1998 through July 2001. The costs during diagnosis, chemotherapy, and terminal care were evaluated according to Japanese National Health Insurance fee schedule. RESULTS: Costs were evaluated in 13 patients receiving TS-1 and in 10 patients receiving conventional intravenous chemotherapy. Monthly costs during diagnosis, chemotherapy, and terminal care in the TS-1 group were 597,057 +/-/105,148 (mean +/-SE) Yen, 327,640 +/1 47,647 Yen, and 687,595 +/-/96,276 Yen. The corresponding costs for conventional intravenous chemotherapy were 615,150 +/1/95,299 Yen, 852,874 +/-/ 62,412 Yen, and 619,721 +/-/ 86,745 Yen. Monthly costs during chemotherapy were significantly lower in the TS-1 group than in the conventional intravenous chemotherapy group, whereas costs during diagnosis and terminal care were similar in the groups. CONCLU-SIONS: Medical costs from diagnosis through terminal care are high in patients with advanced or recurrent gastric cancer. The use of oral anticancer drugs such as TS-1, which facilitates transition from inpatient to ambulatory treatment, reduces medical costs in patients with gastric cancer. We conducted a cohort study in one centre to collect medical data from diagnosis until date of last news or death. Reimbursements of medical fees were obtained from the French Sickness Fund. For the private sector, fee for service rules are applied; as a consequence, all types of health care consumptions could be identified. Consumptions were further linked to treatment phases (initial treatment, follow-up, palliative care) and medical events (chemotherapy, radiotherapy, relapse, adverse event . . .). Logistic regression was carried out to identify which of the medical characteristics (performance, status, staging, age, localisation) were the main cost drivers. Thirty patients were included and mean duration of follow-up was 13.8 months. Mean total direct costs was estimated at €20,752 per patient, with more than one half for initial radio-chemotherapy (€11,399) phase, around one quarter for follow-up (€4684) and the same for palliative care (€4669). 14 patients died during the study and only 9 received palliative care for an average cost per treated patient of €15,563. RESULTS: Type of care distribution varied according to treatment phases with more hospitalisations and medical procedures during initial treatment, more medication during follow-up and more hospitalisation costs during palliative care. Costs of side effects were very high, particularly those associated with mucositis that concerned all patients with a mean cost of €4582 of which €1607 for hospitalisation. CONCLUSIONS: Logistic regression highlighted the importance of the nodal staging on the mean total cost per patients and on the daily cost: €35 for AJCC stage III, €55 for stage IVa, €93 for stage IVb patients.
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COST REDUCTION IN THE DIAGNOSTIC EVALUATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER USING ENDOSCOPIC ULTRASONOGRAPHY WITH FINE-NEEDLE ASPIRATION
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OBJECTIVES:
The prognosis of non-small cell lung cancer (NSCLC) patients is determined by mediastinal lymph node involvement at the time of diagnosis. The objective of this study was to investigate the cost consequences of using endoscopic ultrasonography with fineneedle aspiration (EUS-FNA) instead of mediastinoscopy (MS) or explorative thoracotomy (ET) in patients with NSCLC and suspected mediastinal involvement on positron emission tomography (PET). METHODS: Potentially operable patients with NSCLC and positive PET were eligible. If EUS-FNA was negative or inconclusive, patients underwent MS. If MS was negative, ET was performed. If EUS-FNA was positive for malignancy, no ET was performed. The primary outcome was the reduction of invasive diagnostic procedures and as a result, the reduction of direct medical costs, assessed from the hospital viewpoint. The time horizon was the diagnostic trajectory until discharge from the hospital. RESULTS: Of 82 patients, 49 (60%) had positive EUS-FNA, and did not undergo invasive diagnostic procedures. In 33 patients (40%) EUS-FNA was either negative (6) or inconclusive (27). Surgical staging by MS or ET was performed in 26 of these 33 patients: 12 patients underwent MS, nine patients had ET, and four patients both procedures. The costs were $1590 for MS and $5822 for ET. The costs for EUS-FNA were $591. Assuming that, without EUS-FNA, all patients would undergo MS, and 15% would need additional ET to reach a diagnosis, the differences in total costs were calculated at $55,000. CONCLUSIONS: Introduction of EUS-FNA in the diag-nostic work-up of NSCLC patients' leads to a reduction of invasive procedures, resulting in cost savings of $669 per patient. In Poland, Gem/Cis is the most advantageous treatment alternative based on cost-minimisation for two out of the four comparators (Pac/Car and Doc/Cis). Using a cost-effectiveness analysis, Gem/Cis is considered costeffective against the other two comparators (Vin/Cis and Pac/Cis). Overall, a claim for cost-effectiveness of Gem/Cis regimens in the treatment of advanced NSCLC is supported. 
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